ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Cidara Wins Sizable First Funding Round

by Lisa M. Jarvis
July 7, 2014 | APPEARED IN VOLUME 92, ISSUE 27

San Diego-based biotech firm Cidara Therapeutics has launched with $32 million in its first round of financing, which was backed by 5AM Ventures, Aisling Capital, Frazier Healthcare, and InterWest Partners. Previously known as K2 Therapeutics, the biotech was started to develop small-molecule immunotherapies that can address fungal infections in patients with compromised immune systems. Cidara’s leadership includes several former executives from Trius Therapeutics, an antibiotics firm bought last year by Cubist Pharmaceuticals.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment